Denali Therapeutics (NASDAQ:DNLI) Insider Sells $39,884.46 in Stock

Key Points

• Carole Ho sold 2,937 shares of Denali Therapeutics Inc. at an average price of $13.58, totaling approximately $39,884, which decreased her ownership in the company to 217,391 shares.
• The stock price of DNLI has dropped 2.4% to $14.46, with a 50-day moving average of $14.30.
• Denali Therapeutics reported a quarterly loss of ($0.72) earnings per share (EPS), beating analysts' estimates of ($0.74).

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) insider Carole Ho sold 2,937 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total transaction of $39,884.46. Following the sale, the insider owned 217,391 shares in the company, valued at $2,952,169.78. The trade was a 1.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Carole Ho also recently made the following trade(s):

• On Wednesday, August 13th, Carole Ho sold 806 shares of Denali Therapeutics stock. The shares were sold at an average price of $14.64, for a total transaction of $11,799.84.

Denali Therapeutics Price Performance

Shares of DNLI stock traded down $0.1350 on Tuesday, hitting $14.6850. 191,318 shares of the stock traded hands, compared to its average volume of 1,404,887. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.27 and a quick ratio of 10.27. The firm has a market cap of $2.15 billion, a price-to-earnings ratio of -5.24 and a beta of 1.36. The firm has a 50 day simple moving average of $14.30 and a two-hundred day simple moving average of $15.19. Denali Therapeutics Inc. has a 52 week low of $10.57 and a 52 week high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.74) by $0.02. During the same quarter in the prior year, the company earned ($0.59) earnings per share. As a group, equities research analysts predict that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Denali Therapeutics

A number of hedge funds have recently modified their holdings of DNLI. Norges Bank purchased a new position in Denali Therapeutics during the second quarter worth about $55,224,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Denali Therapeutics by 88.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,766,916 shares of the company's stock worth $91,996,000 after purchasing an additional 3,184,042 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Denali Therapeutics by 15.9% in the 1st quarter. Wellington Management Group LLP now owns 11,409,598 shares of the company's stock valued at $155,113,000 after acquiring an additional 1,561,647 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of Denali Therapeutics by 42.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,367,234 shares of the company's stock valued at $59,373,000 after acquiring an additional 1,308,619 shares during the period. Finally, Millennium Management LLC increased its holdings in shares of Denali Therapeutics by 269.4% in the 1st quarter. Millennium Management LLC now owns 1,493,068 shares of the company's stock valued at $20,298,000 after acquiring an additional 1,088,844 shares during the period. Hedge funds and other institutional investors own 92.92% of the company's stock.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Morgan Stanley reduced their price target on shares of Denali Therapeutics from $33.00 to $30.00 and set an "overweight" rating on the stock in a report on Monday. Wedbush dropped their price objective on shares of Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. William Blair raised shares of Denali Therapeutics to a "strong-buy" rating in a research note on Thursday, April 24th. TD Cowen upgraded shares of Denali Therapeutics to a "strong-buy" rating in a report on Monday, July 28th. Finally, Bank of America decreased their price objective on shares of Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating for the company in a report on Monday, May 19th. Three analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Denali Therapeutics currently has a consensus rating of "Buy" and an average price target of $33.62.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.